|
|
|
Volumn 14, Issue 76, 2005, Pages 68-70
|
|
A review of new drugs in 2004: Floundering innovation and increased risk-taking
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ATOVAQUONE PLUS PROGUANIL;
BOSENTAN;
BUDESONIDE PLUS FORMOTEROL;
CARBIDOPA PLUS LEVODOPA;
CERIVASTATIN;
CETIRIZINE;
ENFUVIRTIDE;
ENTACAPONE;
ESCITALOPRAM;
EZETIMIBE;
FLUTICASONE PROPIONATE PLUS SALMETEROL;
LARONIDASE;
MANIDIPINE;
MELAGATRAN;
METOPIMAZINE;
MISOPROSTOL;
MORPHINE;
NEW DRUG;
OLANZAPINE;
OLMESARTAN;
PARECOXIB;
RISPERIDONE;
ROFECOXIB;
ROSUVASTATIN;
STIRIPENTOL;
SUMATRIPTAN;
TACROLIMUS;
TOPIRAMATE;
UNINDEXED DRUG;
XIMELAGATRAN;
ATOPIC DERMATITIS;
BLEEDING;
CARDIOVASCULAR DISEASE;
CHRONIC OBSTRUCTIVE LUNG DISEASE;
CLINICAL PRACTICE;
DRUG APPROVAL;
DRUG COST;
DRUG EFFECT;
DRUG EFFICACY;
DRUG FORMULATION;
DRUG INDICATION;
DRUG MARKETING;
DRUG PACKAGING;
DRUG SAFETY;
DRUG SCREENING;
DRUG SURVEILLANCE PROGRAM;
DRUG WITHDRAWAL;
DYSKINESIA;
EUROPE;
FRANCE;
GOVERNMENT;
HARM REDUCTION;
HEALTH CARE ORGANIZATION;
HEALTH CARE PERSONNEL;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
HURLER SYNDROME;
HYPERCHOLESTEROLEMIA;
HYPERTENSION;
INTERNET;
LIVER DISEASE;
MASS MEDIUM;
MEDICAL LITERATURE;
MIGRAINE;
MYOCLONUS EPILEPSY;
PRACTICE GUIDELINE;
PREGNANCY TERMINATION;
PRESCRIPTION;
PUBLIC HEALTH SERVICE;
PULMONARY HYPERTENSION;
REIMBURSEMENT;
REVIEW;
RISK ASSESSMENT;
RISK BENEFIT ANALYSIS;
SCHIZOPHRENIA;
|
|
EID: 17144379291
PISSN: 11677422
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (8)
|
|
References (0)
|